Two hundred and sixteen consecutive patients with MDS and abnormal karyotype treated with hypomethylating agents between 4/04 and 10/12 were reviewed. Median follow-up was 17 months. Using IWG criteria, best responses were complete response (CR) in 79 patients (37%), partial response (PR) in 4 (2%), and hematologic improvement (HI) in 10 (5%). Cytogenetic response (CyR) was achieved in 78 patients (36%): complete (CCyR) in 62 (29%) and partial in 16 (7%). CyR was achieved in 48 of 79 patients (61%) with CR, 1 of 14 (7%) with PR/HI, and in 29 of the 123 (24%) with no morphologic response. Median overall survival (OS) and leukemia-free survival (LFS) for patients with and without CCyR were 21 and 13 months (P 5 .007), and 16 and 9 months (P 5 .001), respectively. By multivariate analysis, the achievement of CCyR was predictive for better OS (HR 5 2.1; P < .001). In conclusion, CyR occurs at a rate of 36% (complete in 29%) in patients with MDS treated with HMA and is not always associated with morphological response. The achievement of CCyR is associated with survival improvement and constitutes a major predictive factor for outcome particularly in patients without morphologic response. Therefore, the achievement of CCyR should be considered a milestone in the management of patients with MDS.
| I N T R O D U C T I O N
The myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic stem cell disorders characterized by peripheral blood cytopenias, bone marrow dysplasia affecting one or more of the hematopoietic stem cell lines, and increased risk of transformation into acute myeloid leukemia (AML).
1 Approximately 20%-30% of patients with MDS are at risk for developing AML and many patients suffer from complications related to cytopenias. 2 Therapy with hypomethylating agents (HMA) is now the standard of care for patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). [3] [4] [5] [6] Therapy with decitabine and 5-azacytidine has resulted in complete response (CR) rates of 7%-35%, median response durations of 9-10 months, and median survival of 20-24 months. [3] [4] [5] [6] predictable by the baseline chromosomal abnormalities. 8 We and others have reported on small series cytogenetic response (CyR) rates in the ranges of 30%-40% following treatment with HMA. [3] [4] [5] [6] 9 In patients with chronic myeloid leukemia, the achievement of CyR, particularly complete, has proven to correlate with better outcome. 10, 11 This was reported initially in patients receiving interferon and later on in patients treated with tyrosine kinase inhibitors. Patients with complete cytogenetic response (CCyR) had less transformation and better overall survival. Similarly, patients with acute myeloid leukemia and cytogenetic abnormalities at the time of complete response had significantly shorter relapse-free and overall survival compared with patients with normal cytogenetics at the time of achieving a complete response. 12 However, this phenomenon has not been examined systematically in patients with MDS, where the criteria of response are still predominantly based on morphologic basis. 13 The aim of this study was to assess the impact of achieving a cytogenetic response on outcome of patients with MDS treated with HMA. Moreover, chromosomal abnormality was defined by structural change or gain in at least two metaphases and loss in three metaphases. Fluorescent in situ hybridization (FISH) was conducted to confirm the clonality of the cytogenetic abnormalities in patients exhibiting structural change or gain in less than two metaphases or loss in less than three metaphases.
| P A T I E NT S A ND M E T H O DS
Baseline cytogenetics were classified according to the revised International Prognostic Scoring System (R-IPSS). 16 CCyR was defined as the achievement of a diploid karyotype among at least 20 metaphases analyzed. Partial cytogenetic response (PCyR) was defined as the reduction of 50% of the abnormal metaphases without the acquisition of any new abnormality among at least twenty metaphases analyzed. [18] [19] [20] In a confirmatory second step, we performed a landmark analysis, using as start point the date of achievement of cytogenetic response (either complete or partial) for those who achieved it and the date of cytogenetic assessment for those who did not. This way, the time from therapy start to cytogenetic response, which is the confounding factor, was taken off the analysis. In an additional analysis, and to limit the effect of allogeneic stem cell transplantation (ASCT) on outcome, we performed univariate and multivariate analyses censoring at the time of ASCT.
| R E S U L T S 3.1 | Patients characteristics
Of the 460 patients treated at our institution with HMA therapy, 216 (47%) patients had abnormal baseline karyotype and therefore eligible for this study. Clinical characteristics of the study group (N 5 216) are detailed in Table 1 ], both on clinical trials and predefined marrow evaluations.
Among the 216 patients analyzed, 60 (28%) patients were referred and received ASCT after a median of 7 (4.5-9.5) months from diagnosis.
| Overall clinical response
Responses are summarized in The median time to cytogenetic and morphologic response was 3 (range, 1-27) and 3 (range, 1-45) months, respectively. Of note, only three patients received therapy beyond 6 cycles. Two of them achieved a cytogenetic response after 7 cycles and one after 13 cycles of therapy. The median duration of cytogenetic and morphologic response was 8 (range, 1-59) and 6 (range, 1-48) months, respectively.
We explored the correlation between morphologic response and CyR: 48 of the 79 patients (61%) with CR achieved a CyR; of these, CCyR was achieved in 42 (54%) and PCyR in 6 (8%). One of the 4 patients (25%) with PR achieved a CCyR, and none of the 10 patients (0%) with HI achieved a CyR. Of note, CyR was observed in 29 (24%) among the 123 patients refractory to therapy. The rates of CCyR and PCyR were 16% and 8% in these patients, respectively. Supporting Information Table 1 summarizes correlation between patients' clinical characteristics and CyR. The rate of CyR in patients with very poor cytogenetics was high (46%) as the rate of CyR in patients with very good cytogenetic (40%) (P 5 not significant). Out of 
| Multivariate analysis for survival
We performed univariate and multivariable analysis to determine predictors of LFS and OS (Table 3 ). In the univariate analysis for LFS, presence of anemia, prior chemotherapy, higher-risk R-IPSS, IPSS or MDGSS categories, and lack of achievement of a complete cytogenetic response did correlate with a worse LFS. In the univariate analysis for OS, prior malignancy, prior chemotherapy, and high-risk MDGSS in addition to lack of achievement of a complete cytogenetic response were predictive of a worse OS. In the multivariate analysis, the significant predictive factors of poor LFS were higher-risk R-IPSS categories, and lack of achievement of a complete cytogenetic response. The independent predictive factors for a poor OS were higher-risk MDGSS and lack of achievement of a complete cytogenetic response [P < .001; HR 5 2.1 (95% CI: 1.5-3)].
To further confirm the impact of the achievement of complete cytogenetic response on outcome, we performed a landmark analysis, using as start point the date of achievement of cytogenetic response (either complete or partial) for those who achieved it and the date of cytogenetic assessment for those who did not. This way, the time from therapy start to cytogenetic response, which is the confounding factor, was taken off the analysis. In this analysis, the achievement of complete cytogenetic response remains independent predictive factor for survival [P 5 .008; HR 5 1.6 (95% CI, 1.1-2.4)] and leukemia-free survival [P 5 .003; HR 5 1.8 (95% CI, 1.2-2.6)] (Supporting Information Figure 3A and B).
To understand the effect of allogeneic stem cell transplantation, we performed a subsequent univariate and multivariate analyses censoring at the time of ASCT. In this analysis, the achievement of CCyR remained a major predictive factor for LFS [P 5 .002; HR 5 1.9 (95% CI; 1.3-2.9)] and overall survival [P 5 .001; HR 5 2.1 (95% CI; 1.4-3.
2)]
(Supporting Information Figure 4A and B).
| DISCUSSION
In this report, we show that in patients with MDS treated with HMA, cytogenetic response occurs at in 36% of patients, being complete in 29%. We have additionally shown that the achievement of a complete cytogenetic response is significantly associated with survival improvement in patients with MDS and no morphological response. Our CyR rates were similar to the rates reported in other independent studies using HMA. [3] [4] [5] [6] Similarly to the study reported by Li et al, the achievement of a CyR was associated with survival improvement, with a median survival of 20 months compared with 12 months in patients without a CyR. 9 It has been clearly established that the achievement of a CyR, particularly complete, is the most important prognostic factor for longterm outcome in patients with chronic and acute myeloid leukemia. [10] [11] [12] Furthermore, the depth of the response is crucial for an improvement of event-free and overall survival. 11 Our current study suggests similar phenomenon in MDS and as such the achievement of a CCyR should be considered a milestone in the management of these patients.
Of importance, there was no relationship between morphological response and CyR. In fact, in our study, among the 123 patients considered not responding according to the IWG criteria, 24% had a CyR (complete in 15%). This is similar to the experience with lenalidomide in patients with MDS and chromosome 5q abnormalities, where the CCyR rate was 44%, whereas the morphologic CR rate was only 27%. 22 Furthermore, outcome of patients with CyR and lack of morphologic response was similar to patients achieving a morphologic response after HMA therapy. There are several hypothetical explanations to this phenomenon. One possibility could be purely subjective due to the pathologist reviewing the slides. We have previously reported, among pathologists, a discordance rate of 12% in the diagnosis of patients with MDS. 23 A consensus assessment of response by multiple experienced pathologists and integration of genetic and molecular markers in the response assessment will significantly decrease this gap. Another possibility could be the existence of a lag phase between early progenitors and later dividing precursors; repeating the assessment a week or two later can further elucidate the gap.
Finally, that could be explained by the heterogeneity of the disease, where patients can harbor different clones with and without abnormal karyotype that can coexist at the same time. As such in patients with no morphologic response, a clone with abnormal karyotype could be suppressed while other disease clones with somatic point mutations and normal karyotype were not.
There are several limitations to our study. Because of the retrospective nature of the study design, schedule and frequency of bone marrow exams were not controlled throughout the cohort. We have previously reported on the importance of a close cytogenetic monitoring of such patients where the acquisition of a new cytogenetic clone could reflect genomic instability and imminent transformation, 24 and as such we are implementing prospectively a close monitoring with marrow samples for morphologic cytogenetic and molecular assessment every 3 the first year and then every 6 months thereafter. Second, in our study, we did not take into account for the increasingly identified molecular alterations and somatic point mutations and its correlation with long-term outcome. 25, 26 It is of great interest to investigate association between these molecular markers, response to therapy (minimal residual disease), and subsequent disease progression and survival.
With all these limitations, the data presented here indicate that the achievement of a CCyR is a major milestone in the management of patients with MDS.
In conclusion, the achievement of a CyR, particularly complete, in patients with MDS and cytogenetic abnormalities treated with HMA occurs in close to a third of the patients and is the major parameter associated with survival improvement, particularly among patients not in morphologic response. As such this constitutes a major milestone and should be added to the morphologic criteria already in use.
Sequential cytogenetic analyses may allow the identification of subsets of patients with MDS at higher risk for progression and thus might guide treatment decisions in the future. 
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